Brilinta (ticagrelor) causes shortness of breath because it raises levels of a natural signaling molecule called adenosine in your body. This is the most common side effect of the drug, affecting roughly 10% to 15% of patients after an acute coronary event, and up to 39% in clinical study settings. The good news: it’s almost always harmless and temporary, even though it can feel alarming.
How Brilinta Triggers Breathlessness
Brilinta works by blocking a receptor on your platelets to prevent blood clots. But unlike similar blood thinners, it has a second effect: it slows the way your cells absorb adenosine, a molecule your body produces naturally. When adenosine builds up in your bloodstream, it stimulates nerve endings in your lungs that sense how much air you’re getting. Those nerves send a signal to your brain that you’re not breathing enough, even though your oxygen levels are perfectly normal.
This is why the breathlessness from Brilinta feels different from being winded after exercise or struggling to breathe during an asthma attack. Your lungs are working fine. Your heart is pumping normally. The problem is a false alarm in the signaling pathway between your lungs and brain.
What the Episodes Feel Like
Brilinta-related breathlessness has a distinctive pattern that sets it apart from more serious causes. It typically starts about two hours after taking a dose. Each episode is brief, lasting only one to two minutes before fading as quickly as it came. These short bursts can recur multiple times over a few hours or even a few days, which understandably makes people worry something is wrong with their heart or lungs.
In the ONSET/OFFSET clinical trial, most instances were mild and lasted less than 24 hours total. Of the patients who experienced breathlessness on ticagrelor, 8 out of 22 noticed it within the first 24 hours of starting the drug, and 17 out of 22 experienced it within the first week. Only 3 patients in that study found it bothersome enough to stop taking the medication.
How Common It Is Compared to Other Blood Thinners
Brilinta causes significantly more breathlessness than its main alternative, clopidogrel (Plavix). In the ONSET/OFFSET trial, 38.6% of patients on ticagrelor reported dyspnea compared to just 9.3% on clopidogrel and 8.3% on placebo. That placebo number is worth noting: some degree of breathlessness is common in people with heart disease regardless of which medication they take.
A study of East Asian patients with acute coronary syndrome found that within one month of starting treatment, 26.3% of those on ticagrelor experienced breathlessness versus 13.6% on clopidogrel. After adjusting for other factors, ticagrelor more than doubled the odds of developing breathlessness (odds ratio of 2.19). This effect was consistent across different patient populations and study designs, confirming it’s a real pharmacological effect of the drug rather than a coincidence.
Whether It Goes Away on Its Own
For most people, yes. The current recommendation is to continue taking Brilinta and monitor symptoms for three to four days, because the episodes typically disappear within that window. Your body appears to adjust to the elevated adenosine levels, and the false breathing alarms quiet down.
This is an important point if you’ve just started the medication and are feeling panicked. Brilinta is prescribed after heart attacks and stent placements because it reduces the risk of another cardiovascular event. Stopping it abruptly carries real danger, particularly if you have a recently placed stent. The breathlessness, while uncomfortable, does not reflect actual impairment of your heart or lung function.
When Breathlessness Needs Attention
The challenge is that people taking Brilinta are heart patients, and shortness of breath can also signal heart failure, a new clot, fluid in the lungs, or other complications that genuinely need treatment. The pattern of symptoms matters here.
Brilinta-related breathlessness comes in short, discrete episodes lasting a minute or two. It appears within hours of a dose and resolves quickly. It doesn’t come with chest pain, swelling in your legs, coughing up pink or frothy fluid, or a feeling that you can’t breathe while lying flat. If your breathlessness is continuous, getting worse over days, wakes you from sleep, or comes with any of those additional symptoms, that pattern points away from a medication side effect and toward something your cardiologist needs to evaluate.
The 2025 ACC/AHA guidelines for managing acute coronary syndromes specifically note that ticagrelor causes “subjective transient dyspnea,” reinforcing that cardiologists expect this side effect and distinguish it from worsening heart disease. If you’re unsure whether what you’re feeling fits the typical Brilinta pattern, calling your prescribing doctor is reasonable. They can often sort it out quickly over the phone based on your symptom description, and if needed, a simple oxygen check or lung function test can confirm everything is working normally.
What Happens If You Can’t Tolerate It
A small percentage of patients find the breathlessness persistent or severe enough that it affects their quality of life. In those cases, switching to clopidogrel is the standard alternative. Clopidogrel works through a similar mechanism to prevent clots but doesn’t affect adenosine levels, which is why it causes far less breathlessness. The tradeoff is that ticagrelor has shown slightly better outcomes in preventing repeat cardiovascular events in some patient populations, so the decision involves weighing that benefit against the side effect burden.
If you do switch, the breathlessness resolves once ticagrelor clears your system. The drug has a relatively short duration of action compared to clopidogrel, so symptoms typically fade within a day or two of stopping.